CTMX lead EpCAM ADC shows robust efficacy in late-line CRC
CTMX’s lead EpCAM-targeting ADC reported robust efficacy in late-line colorectal cancer at a conference, alongside manageable safety and a clear regulatory path. The company also highlighted expansion into combinations and other GI tumors.